Jump Financial, LLC Allovir, Inc. Transaction History

Jump Financial, LLC

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	SELL	$0.7 - $0.82 $10,195 - $11,943	-14,565 Closed	0 $0
Q2 2024 Aug 14, 2024	BUY	$0.72 - $0.82 $10,486 - $11,943	14,565 New	14,565 $10,000
Q3 2023 Oct 21, 2024	BUY	$2.15 - $3.64 $46,936 - $79,464	21,831 Added 149.89%	36,396 $78,000
Q3 2023 Nov 07, 2023	BUY	$2.15 - $3.64 $78,251 - $132,481	36,396 New	36,396 $78,000
Q4 2022 Feb 13, 2023	BUY	$4.7 - $9.98 $175,573 - $372,812	37,356 New	37,356 $191,000
Q2 2022 Aug 09, 2022	SELL	$3.26 - $7.06 $50,790 - $109,994	-15,580 Reduced 53.72%	13,420 $52,000
Q1 2022 May 12, 2022	BUY	$6.75 - $13.52 $195,750 - $392,080	29,000 New	29,000 $196,000
Q4 2021 Feb 10, 2022	SELL	$12.94 - $25.99 $197,037 - $395,749	-15,227 Closed	0 $0
Q3 2021 Nov 12, 2021	BUY	$16.97 - $25.06 $258,402 - $381,588	15,227 New	15,227 $381,000
Q2 2021 Aug 13, 2021	SELL	$19.44 - $25.06 $291,638 - $375,950	-15,002 Closed	0 $0
Q1 2021 May 17, 2021	BUY	$20.81 - $45.5 $312,191 - $682,591	15,002 New	15,002 $351,000

44.6M

14.9K

200

Ticker ALVR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 93,063,400
Market Cap $53M
Description
Allovir, Inc., a clinical-stage cell therapy company, engages in the research and development of allogeneic, off-the-shelf multi-virus specific T cell (VST) therapies to prevent and treat devastating viral-associated diseases. The company's lead product is posoleucel, an allogeneic, off-the-shelf VST therapy, to treat BK virus, cytomegalovirus, ...

Get notified when there are updates to the investment portfolio of Jump Financial, LLC, based on Form 13F filings with the SEC.

Stay updated on Jump Financial, LLC with notifications on news.